Immunization of @entity19 with a live transconjugant Shigella hybrid strain induced XXXX and Th17 cell mediated immune responses and confirmed passive protection against heterologous Shigellae.

@entity6835 @entity58744 @entity14293 @entity19 @entity635 @entity1618 @entity636 @entity630
UNASSIGNED: An avirulent, live transconjugant Shigella hybrid (LTSH  @entity58744 ) strain was constructed in our earlier study by introducing a plasmid vector, pPR1347, into a Shiga-toxingene deleted Shigella dysenteriae1. Three successive oral administrations of LTSH  @entity58744 to female adult @entity19 produced comprehensive passive heterologous protection in their offspring against challenge with wild type shigellae. Production of NO and different cytokines such asIL-12p70, @entity635 and @entity14293 in peritoneal @entity19 macrophages indicated that LTSH  @entity58744 induced innate and adaptive immunity in @entity19 . Furthermore, production of IFN-y, @entity1618 and @entity636 in LTSH-primed splenic CD4+ T-cell suggested that LTSH  @entity58744 may induce @entity630 and Th17 cellmediated immune responses. Exponential increase of the serum IgG and IgA titer against whole shigellae were observed in immunized adult @entity19 during and after the immunization with the highest peak on day 35. Antigen specific sIgA was also determined from intestinal lavage of immunized @entity19 . The stomach extracts of neonates from immunizedmice, mainly containing mother's milk, contained significant levels of anti-LTSH  @entity58744 immunoglobulin. These studies suggest that the LTSH  @entity58744 could be a new live oral vaccinecandidate against @entity6835 in the near future. This article is protected by copyright. All rights reserved.
